During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Björn&nbsp;Chapuy, Universitätsmedizin&nbsp;Göttingen, Göttingen,&nbsp;DE,&nbsp;and University Hospital Tübingen, Tübingen, DE. We asked, What is the role of genetic classification in the diagnosis of diffuse large B-cell lymphoma (DLBCL)? Chapuy and de&nbsp;Fend begin by discussing the role of genetic classification and heterogeneity in DLBCL and explore the current obstacle of how to utilize this in routine diagnostics. They go on to highlight the need for clinical trials, and Chapuy&nbsp;outlines a novel clinical trial presented at ICML. Finally, they recap the journey from refining molecular understanding to clinical decision-making.<hr> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.

What are the recent advances in antibody-drug conjugates for lymphoma treatment?

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.